相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1834
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Sexual orientation minority women had 16% lower breast cancer and 8% lower cervical cancer screening adherence compared with heterosexual women, according to a cross-sectional analysis of 663,924 US adults. - Gender identity minority individuals showed a 76% lower likelihood of breast cancer screening and a 42% lower likelihood of cervical cancer screening versus cisgender individuals. - Colorectal cancer screening adherence was 10% higher among sexual orientation minority men, with no differences observed based on gender identity. - Researchers call for multipronged interventions at the health system, policy, and payer levels to eliminate structural barriers and ensure equitable access to preventive cancer care.
- Histotripsy is a noninvasive focused-ultrasound technique that mechanically destroys liver tumor tissue through cavitation bubble clouds, unlike thermal ablation methods. - The FDA cleared the first histotripsy system for liver tumors in 2023 based on the HOPE4LIVER trial, confirming short-term safety and technical success. - UAMS has become the first provider in Arkansas to offer histotripsy, with treatment sessions lasting about 20–30 minutes per tumor under general anesthesia on an outpatient basis. - Long-term efficacy data, including progression-free and overall survival, remain unevaluated, and the technology is currently limited to small, ultrasound-visible tumors.
- A prospective clinical trial at Ohio State University demonstrated that Prospera-guided monitoring allowed physicians to safely omit routine 9-month surveillance biopsies in approximately 75% of low-risk lung transplant patients. - The study of 78 lung transplant recipients showed that 95% of patients who skipped the 9-month biopsy remained free of acute rejection requiring treatment at one year post-transplant. - Patients who omitted the invasive procedure maintained similar lung function and immunologic stability compared to those who underwent the standard biopsy protocol. - The donor-derived cell-free DNA surveillance approach could significantly reduce procedural risks and healthcare costs while maintaining patient safety in lung transplant monitoring.
- Renerva Inc received FDA Investigational Device Exemption approval to begin first-in-human clinical trials of its PNM-CAP nerve capping device at The Ohio State University Wexner Medical Center. - The device is designed to prevent neuroma formation and chronic pain following nerve transection during amputation procedures, addressing a critical unmet need for over 2 million US amputees. - Preclinical studies published in npj Regenerative Medicine demonstrated up to 16-fold reduction in nerve growth and 3.5-fold reduction in pain behavior compared to standard care controls. - The clinical trial will enroll 10 patients over one year to evaluate the device's ability to reduce pain, limit opioid consumption, and improve quality of life for amputation patients.
- HCW Biologics has dosed the first patient in a Phase 1 clinical trial evaluating HCW9302, a novel interleukin-2 fusion molecule, for treating alopecia areata at The Ohio State University Wexner Medical Center. - The therapy targets regulatory T cells to control excessive inflammation that causes autoimmune hair loss, representing a first-in-kind approach for the 160 million people worldwide affected by alopecia areata. - The multi-center dose-escalation study will treat up to 30 patients to establish safety and determine the recommended Phase 2 dose, with potential expansion to other autoimmune conditions like vitiligo and atopic dermatitis. - HCW9302 demonstrated good tolerability in non-human primate studies and aims to address the lack of curative FDA-approved treatments for this condition that significantly impacts patients' quality of life.
- A randomized controlled trial of 339 psychiatric inpatients found that the OTX-202 mobile app reduced post-discharge suicide attempts by 58.3% among patients with previous suicide attempts. - The app delivered suicide-specific therapy and sustained reductions in suicidal thoughts for up to 24 weeks, while control group patients experienced rebound symptoms by week 24. - The study addresses a critical treatment gap, as suicide is the only top killer without prescription products for most at-risk patients, costing the U.S. healthcare system $500 billion annually. - OTX-202, developed by Oui Therapeutics, offers a scalable solution during the high-risk period following psychiatric hospitalization when access to specialized therapists is limited.
- Zilucoplan, a macrocyclic peptide complement C5 inhibitor approved by FDA in October 2023, demonstrates sustained efficacy over 120 weeks in treating AChR antibody-positive generalized myasthenia gravis patients. - The RAISE-XT extension study revealed that nearly 30% of patients successfully reduced or discontinued nonsteroidal immunosuppressive therapy by week 120 while maintaining clinical benefits. - Zilucoplan's unique molecular structure as a macrocyclic peptide provides faster onset and potentially superior tissue penetration compared to monoclonal antibody complement inhibitors. - The subcutaneous daily administration offers patient preference advantages over IV infusions, with switching studies showing maintained or improved efficacy when transitioning from other complement inhibitors.
- Mirvie's blood test successfully identified 91% of preterm preeclampsia cases in women over 35 without pre-existing conditions, using RNA signatures detectable at 17.5-22 weeks gestation. - The study analyzed over 9,000 pregnancies and discovered molecular signatures that distinguish between severe and mild hypertensive disorders of pregnancy for the first time. - Preeclampsia rates have nearly doubled in the past decade, now affecting 1 in 12 pregnancies, highlighting the urgent need for better predictive tools. - The clinically validated test will be available under the Encompass brand, enabling proactive care plans including low-dose aspirin therapy months before symptoms appear.
- A randomized clinical trial found that brief cognitive behavioral therapy (CBT) delivered via telehealth effectively reduces suicide attempts and suicidal ideation. - The study compared brief CBT to present-centered therapy, demonstrating CBT's superiority in reducing suicide attempts among adults with recent suicidal thoughts or behaviors. - Researchers emphasize that telehealth CBT can increase access to evidence-based treatments, especially for individuals in rural or underserved areas. - The findings support the use of virtual mental health care to safely and effectively treat high-risk suicidal patients, expanding care options post-COVID-19 pandemic.
- AI technology is transforming cancer care by integrating patient factors like tumor microenvironment, demographics, and family history to deliver more precise diagnoses and treatment predictions. - Advanced AI tools can differentiate between visually similar prostate cancers by analyzing multiple factors, enabling more accurate prediction of disease progression and treatment outcomes. - The role of pathologists has evolved from purely diagnostic to becoming integral members of patient care teams, utilizing AI to provide comprehensive patient profiles for targeted therapies.
